Metabolic syndrome in psychiatric inpatients treated for depression

Modern Trends in Pharmacopsychiatry

Volumn 26, Issue , 2009, Pages 90-104

  Goethe, John W ^a   Szarek, Bonnie L ^a   Caley, Charles F ^a,b  

^a INSTITUTE OF LIVING   (United States)

^b UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; BENZODIAZEPINE; CLOZAPINE; GABAPENTIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LAMOTRIGINE; LITHIUM; MIRTAZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; TOPIRAMATE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID; VENLAFAXINE; ZIPRASIDONE;

ADULT; ARTICLE; BORDERLINE STATE; CLINICAL FEATURE; DEMOGRAPHY; FEMALE; GLUCOSE BLOOD LEVEL; HOSPITAL ADMISSION; HOSPITAL PATIENT; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; METABOLIC SYNDROME X; PREVALENCE; RISK FACTOR; SEX DIFFERENCE; URBAN AREA;

EID: 67649988387     PISSN: 16622685     EISSN: 16624505     Source Type: Book Series    
DOI: 10.1159/000189777     Document Type: Article

References (64)

1. Newcomer JW: Second generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005;19(suppl 1):1-93.
2. Heiskanen TH, Niskanen LK, Hintikka JJ, et al: Metabolic syndrome and depression: a cross-sectional analysis. J Clin Psychiatry 2006;67:1422-1427.
3. McEvoy JP, Meyer JM, Goff DC, et al: Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 2005;80:19-32.
4. Ford ES, Giles WH, Mokdad AH: Increasing prevalence of the metabolic syndrome among US adults. Diabetes Care 2004;27:2444-2449.
5. Kinder LS, Carnethon MR, Palaniappan LP, King AC, Fortmann SP: Depression and the metabolic syndrome in young adults: findings from the Third National Health and Nutrition Examination Survey. Psychosom Med 2004;66:316-322.
6. Raikkonen K, Matthews KA, Kuller LH: Depressive symptoms and stressful life events predict metabolic syndrome among middle-aged women. Diabetes Care 2007;30:872-877.
7. Goethe JW, Szarek BL, Woolley SB, Caley CF: Metabolic syndrome in psychiatric inpatients. Annual Meeting of the American Psychiatric Association, San Diego, 2007.
8. Everson-Rose SA, Meyer PM, Powell LH, et al: Depressive symptoms, insulin resistance, and risk of diabetes in women at midlife. Diabetes Care 2004;27:2856-2862.
9. Bryan CJ, Songer TJ, Brooks MM, et al: A comparison of baseline sociodemographic and clinical characteristics between major depressive disorder patients with and without diabetes: a STAR*D report. J Affect Disord 2008;108:113-120.
10. Koponen H, Jokelainen J, Keinanen-Kiukaanniemi S, Kumulsalo E, Vanhala M: Metabolic syndrome predisposes to depressive symptoms: a population-based 7-year follow-up study. J Clin Psychiatry 2008;69:178-182.
11. Skilton JR, Moulin P, Terra J-L, Bonnet F: Associations between anxiety, depression, and the metabolic syndrome. Biol Psychiatry 2007;62:1251-1257.
12. Grundy SM, Cleeman JI, Daniels SR, et al: Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, and Blood Institute Scientific Statement. Circulation 2005;112:2735-2752.
13. Goethe JW, Szarek BL, Caley CF: Metabolic syndrome and depression: a review. Depression Mind Body 2008;3:138-149.
14. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evalulation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Final Report. Circulation 2002;106:3143-3421.
15. Balkau B, Charles MA: Comment on the provisional report from the WHO consultation European Group for the Study of Insulin Resistance (EGIR). Diabet Med 1999;16:442-443.
16. Alberti KG, Zimmet P, Shaw J, IDF Epidemiology Task Force Consensus Group: The metabolic syndrome: a new worldwide definition. Lancet 2005;366:1059-1062.
17. Alberti KG, Zimmet PZ: Definition, diagnosis and classification of diabetes mellitus and its complications. 1. Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15:539-553.
18. Einhorn D: ACE position statement on insulin resistance syndrome. Endocr Pract 2003;9:237-252.
19. Centers for Disease Control and Prevention (CDC): National Center for Health Statistics (NCHS). National Health and Nutrition Examination Survey Data. Hyattsville, MD: US Department of Health and Human Services, Centers for Disease Control and Prevention, 2003-2004, 222.edu.gov/nchs/nhames.htm.
20. Grundy SM, Benjamin IJ, Burke GL, et al: Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 1999;100:1134-1146.
21. Kroeze WK, Hufeisen SJ, Popadak BA, Renock SM, Steinberg S, Ernsberger P, Jayathilake K, Meltzer HY, Roth BL: H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 2003;28:519-526.
22. Reynolds GP, Zhang AJ, Zhang XB: Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism. Lancet 2002;359:2086-2087.
23. Ellingrod VL, Perry PJ, Ringold JC, Lund BC, Bever-Stille K, Fleming F, Holman TL, Miller D: Weight gain with the -759 C/T polymorphism of the 5HT2C receptor and olanzapine. Am J Med Genet [B] 2005;134:76-78.
24. Wirshing DA, Wirshing WC, Kysar L, Berisford MA, Goldstein D, Pashdag J, Mintz J, Marder SR: Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry 1999;60:358-363.
25. Tecott LH, Sun LM, Akana SF, Strack AM, Lowenstein DH, Dallman MF, Julius D: Eating disorder and epilepsy in mice lacking 5-HT2C serotonin receptors. Nature 1995;374:542-546.
26. Newcomer JW: Antipsychotic medications: metabolic and cardiovascular risk. J Clin Psychiatry 2007;68(suppl 14):8-13.
27. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity: Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry 2004;65:267-272.
28. Grundy SM: Metabolic syndrome: a multiplex cardiovascular risk factor. J Clin Endocrinol Metab 2007;92:399-404.
29. Wirshing DA, Boyd JA, Meng LR, Ballon JS, Marder SR, Wirshing WC: The effects of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry 2002;63:856-865.
30. Effexor Product Information. Wyeth Pharmaceuticals, Philadelphia, 2008.
31. Teitelbaum M: Severe hypertriglyceridemia secondary to venlafaxine and fluoxetine (letter to the editor). Psychosomatics 2001;42:440-441.
32. Organon: Remeron (mirtazapine) package insert. West Orange, Organon, 2001.
33. Raeder MB, Bjelland I, Vollset SE, Steen VM: Obesity, dyslipidemia, and diabetes with selective serotonin reuptake inhibitors: the Hordaland Health Study. J Clin Psychiatry 2006;67:1974-1982.
34. Cardenas J, Frye MA, Marusak SL, et al: Modal subcomponents of metabolic syndrome in patients with bipolar disorder. J Affect Disord. 2008;106:91-97.
35. Livingstone C, Rampes H: Lithium: a review of its metabolic adverse effects. J Psychopharmacol 2006;20:347-355.
36. Anon: Mood stabilizers; in Perry PJ, Alexander B, Liskow BI, DeVane CL (eds): Psychotropic Drug Handbook. Philadelphia, Lippincott Williams & Wilkins, 2007, pp 226-295.
37. Fankhauser M, Kreuger R, Finley P: Triglyceride and cholesterol concentrations in serum during chronic lithium therapy: a retrospective comparison of baseline and follow-up laboratory values. Lithium 1991;2:77-81.
38. Bowden CL: Valproate. Bipolar Disorders 2003;5:189-202.
39. Bowden CL, Singh V: Valproate in bipolar disorder: 2000 onwards. Acta Psychiatr Scand 2005;111(suppl 426):13-20.
40. Verrotti A, Basciani F, De Simone M, Trotta D, Morgese G, Chiarelli F: Insulin resistance in epileptic girls who gain weight after therapy with valproic acid. J Child Neurol 2002;17:265-268.
41. Post RM, Ketter TA, Uhde T, Ballenger JC: Thirty years of clinical experience with carbamazepine in the treatment of bipolar illness: principles and practice. CNS Drugs 2007;21:47-71.
42. Weisler RH, Hirschfeld, Cutler AJ, Gazda T, Ketter TA, Keck PE, Swann A, Kalali A, et al: Extended-release carbamazepine capsules as monotherapy in bipolar disorder. Pooled results from two randomized, double-blind, placebo-controlled trials. CNS Drugs 2006;20:219-231.
43. Joffe RT, Post RM, Uhde TW: Effect of carbamazepine on body weight in affectively ill patients. J Clin Psychiatry 1986;47:313-314.
44. Brown DW, Ketter TA, Crumlish J, Post RM: Carbamazepine-induced increases in total serum cholesterol: clinical and theoretical implications. J Clin Psychopharmacol 1992;12:431-437.
45. Bowden CL, Calabrese JR, Ketter TA, Sachs GS, White RL, Thompson TR: Impact of lamotrigine and lithium on weight in obese and nonobese patients with bipolar I disorder. Am J Psychiatry 2006;163:1199-1201.
46. Brown EB, McElroy SL, Keck PE, Deldar A, Adams DH, Tohen M, et al: A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression. J Clin Psychiatry 2006;67:1025-1033.
47. Lamictal Product Information. Research Triangle Park, Glaxo Smith Kline, 2007.
48. Neurontin Product Information. New York, Pfizer Pharmaceuticals, 2005.
49. Morris GL: Gabapentin. Epilepsia 1999;40(suppl 5):S63-S70.
50. DeToledo JC, Toledo C, DeCerce J, Ramsay RE: Changes in body weight with chronic, high-dose gabapentin therapy. Ther Drug Monit 1997;19:394-396.
51. Ben-Menachem E: Weight issues for people with epilepsy: a review. Epilepsia 2007;48(suppl 9):42-45.
52. Maggioni F, Ruffatti S, Dainese F, Mainardi F, Zanchin G: Weight variations in the prophylactic therapy of primary headaches: 6-month follow-up. J Headache Pain 2005;6:322-324.
53. Jallon P, Picard F: Bodyweight gain and anticonvulsants: a comparative review. Drug Saf 2001;24:969-978.
54. Pasco JA, Jacka FN, Williams LJ, et al: Leptin in depressed women: cross sectional and longitudinal data from an epidemiologic study. J Affect Disord 2008;107:221-225.
55. Vestri HS, Maianu L, Moellering DR, Garvey WT: Atypical antipsychotic drugs directly impair insulin action in adipocytes: effects on glucose transport, lipogenesis, and antilipolysis (see comment). Neuropsychopharmacology 2007;32:765-772.
56. Gilmer WS, Trivedi MH, Rush AJ, Wisniewski SR, Luther J, Howland RH, Yohanna D, Khan A, Alpert J: Factors associated with chronic depressive episodes: a preliminary report from the STAR-D project. Acta Psychiatr Scand 2005;112:425-433.
57. Brown ES, Varghese FP, McEwen BS: Association of depression with medical illness: does cortisol play a role? Biol Psychiatry 2004;55:1-9.
58. Carnethon MR, Biggs ML, Barzilay JI, et al: Longitudinal association between depressive symptoms and incident type 2 diabetes mellitus in older adults: the cardiovascular health study. Arch Intern Med 2007;167:802-807.
59. Baptista T, Martinez J, Lacruz AN, et al: Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial. Can J Psychiatry 2006;51:192-196.
60. Wu R-R, Zhao J-P, Jin H, Shao P, Fang M-S, Guo X-F, et al: Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial. JAMA 2008;299:185-193.
61. Baptista T, Sandia I, Lacruz A, et al: Insulin counter-regulatory factors, fibrinogen and C-reactive protein during olanzapine administration: effects of the antidiabetic metformin. Int Clin Psychopharmacol 2007;22:69-76.
62. Baptista T, Rangel N, Fernandez V, et al: Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double-blind, placebo-controlled trial. Schizophr Res 2007;93:99-108.
63. Klein DJ, Cottingham EM, Sorter M, Barton BA, Morrison JA: A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents. Am J Psychiatry 2006;163:2072-2079.
64. Gaede P, Lund-Andersen H, Parving H-H, Pedersen O: Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008;358:580-591.